US › Healthcare

Olema Pharmaceuticals Inc (OLMA)

US · Healthcare · Biotechnology

$11.76+4.26%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-53.1M
Profit YoY
-74.7%
EPS
$-0.52
EPS estimate
$-0.54

EPS came in at -0.52 against a street estimate of -0.54 — a beat of 3.7%.

Key statistics

Market cap
$1.00B
Forward P/E
0.0
P/B
2.08
Book value
$5.50
EPS (TTM)
$-2.03
52-week high
$36.26
52-week low
$4.47
50-day MA
$11.53
200-day MA
$17.45
Beta
2.01

Analyst view

Analysts rate Olema Pharmaceuticals Inc a strong buy (8 buy, 0 hold, 0 sell out of 8) with an average price target of $40.70.

Shareholding

Insiders
1.77%
Institutions
118.96%

Largest institutional holders

FundStake
FMR Inc11.89%
Paradigm Biocapital Advisors LP9.18%
Bain Capital Life Sciences Investors, LLC8.56%
HHG PLC8.14%
BlackRock Inc6.47%
Bvf Inc6.06%
Siren, L.L.C.5.45%
State Street Corp4.51%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Olema Pharmaceuticals Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.